Market capitalization | $23.37m |
Enterprise Value | $12.59m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.26 |
P/S ratio (TTM) P/S ratio | 2.33 |
P/B ratio (TTM) P/B ratio | 2.14 |
Revenue growth (TTM) Revenue growth | 47.05% |
Revenue (TTM) Revenue | $10.01m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast Pulmatrix Inc:
1 Analyst has issued a forecast Pulmatrix Inc:
Sep '24 |
+/-
%
|
||
Revenue | 10 10 |
47%
47%
|
|
Gross Profit | - - |
-
|
|
EBITDA | -6.78 -6.78 |
55%
55%
|
EBIT (Operating Income) EBIT | -7.42 -7.42 |
56%
56%
|
Net Profit | -9.66 -9.66 |
41%
41%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products for respiratory and other diseases. The firm focuses on the prevention and treatment of respiratory diseases and infections. It offers products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov, and Robert S. Langer, Jr. on June 15, 2015 and is headquartered in Lexington, MA.
Head office | United States |
CEO | Peter Ludlum |
Employees | 22 |
Founded | 2015 |
Website | www.pulmatrix.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.